Search clinical trials for: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative

Total 433 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Vanderbilt University Medical Center
University of Alabama at Birmingham; University of Washington; Northwestern University...

Recruiting

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Influenza | Transplantation Infection | Solid Organ Transplant | Immunization; Infection

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
National Institute of Allergy and Infectious Diseases...
Baylor College of Medicine; University of Pittsburgh; Ann & Robert H Lurie Children... and other collaborators

Not yet recruiting

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (PSOT)

Influenza | Transplantation Infection | Immunization; Infection

United States
Vanderbilt University Medical Center
University of Alabama at Birmingham; Duke University; University of Washington; Northwestern University Feinberg School of Medicine

Recruiting

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Influenza | Transplantation Infection | Immunization; Infection

United States
Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years (QIV)

Influenza

China
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
Sinovac Biotech Co., Ltd

Active, not recruiting

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

Mumps | Influenza

China
Kaiser Permanente
Sanofi Pasteur, a Sanofi Company

Completed

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Stroke | Pneumonia | Influenza | Congestive Heart Failure | Acute Myocardial Infarction | Lower Respiratory Tract Infection

United States
Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Recruiting

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Suspended

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (QHD00014)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Flublok or Fluzone With Advax-CpG55.2 or AF03

Influenza | Influenza Immunisation

United States
Hospital Israelita Albert Einstein
Ministry of Health, Brazil

Completed

Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes (VIP-ACS)

Acute Coronary Syndrome

Brazil
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Ab&b Biotechnology Co., Ltd.JS
Henan Center for Disease Control and Prevention

Completed

A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months

Influenza

China
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to Influenza Vaccination in Children and Adolescents

Immune Response | Influenza, Human

United States
Seqirus

Completed

Flucelvax (TIVc or QIVc) Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old

Seasonal Influenza

China
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
Osivax
Novotech (Australia) Pty Limited; Harmony Clinical Research; Northern Beaches...

Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
University of Pittsburgh
Sanofi Pasteur, a Sanofi Company

Completed

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Influenza

United States
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain

3

Subscribe